sorafenib has been researched along with Hyperplasia in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Gong, Y; Huang, T; Huang, X; Liu, B; Wang, J; Wang, Z; Yu, Q | 1 |
Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL | 1 |
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I | 1 |
3 other study(ies) available for sorafenib and Hyperplasia
Article | Year |
---|---|
Sorafenib suppresses proliferation rate of fibroblast-like synoviocytes through the arrest of cell cycle in experimental adjuvant arthritis.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Down-Regulation; Fibroblasts; G1 Phase Cell Cycle Checkpoints; Hyperplasia; Mice; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Sorafenib; Synovial Membrane; Synoviocytes | 2021 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib | 2009 |